7z28: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==High-resolution crystal structure of ERAP1 with bound bestatin analogue inhibitor== | ==High-resolution crystal structure of ERAP1 with bound bestatin analogue inhibitor== | ||
<StructureSection load='7z28' size='340' side='right'caption='[[7z28]]' scene=''> | <StructureSection load='7z28' size='340' side='right'caption='[[7z28]], [[Resolution|resolution]] 1.55Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7Z28 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7Z28 FirstGlance]. <br> | <table><tr><td colspan='2'>[[7z28]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7Z28 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7Z28 FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7z28 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7z28 OCA], [https://pdbe.org/7z28 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7z28 RCSB], [https://www.ebi.ac.uk/pdbsum/7z28 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7z28 ProSAT]</span></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=I88:methyl+(2~{S})-2-[[(2~{S})-2-[[(2~{S},3~{R})-3-azanyl-2,7-bis(oxidanyl)heptanoyl]amino]-4-methyl-pentanoyl]amino]-3-(4-hydroxyphenyl)propanoate'>I88</scene>, <scene name='pdbligand=MLT:D-MALATE'>MLT</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PGE:TRIETHYLENE+GLYCOL'>PGE</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7z28 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7z28 OCA], [https://pdbe.org/7z28 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7z28 RCSB], [https://www.ebi.ac.uk/pdbsum/7z28 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7z28 ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | |||
[[https://www.uniprot.org/uniprot/ERAP1_HUMAN ERAP1_HUMAN]] Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides. Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. Strongly prefers substrates 9-16 residues long. Rapidly degrades 13-mer to a 9-mer and then stops. Preferentially hydrolyzes the residue Leu and peptides with a hydrophobic C-terminus, while it has weak activity toward peptides with charged C-terminus. May play a role in the inactivation of peptide hormones. May be involved in the regulation of blood pressure through the inactivation of angiotensin II and/or the generation of bradykinin in the kidney.<ref>PMID:15908954</ref> <ref>PMID:16286653</ref> <ref>PMID:21478864</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The oxytocinase subfamily of M1 zinc aminopeptidases comprises emerging drug targets, including the ER-resident aminopeptidases 1 and 2 (ERAP1 and ERAP2) and insulin-regulated aminopeptidase (IRAP); however, reports on clinically relevant inhibitors are limited. Here we report a new synthetic approach of high diastereo- and regioselectivity for functionalization of the alpha-hydroxy-beta-amino acid scaffold of bestatin. Stereochemistry and mechanism of inhibition were investigated by a high-resolution X-ray crystal structure of ERAP1 in complex with a micromolar inhibitor. By exploring the P1 side-chain functionalities, we achieve significant potency and selectivity, and we report a cell-active, low-nanomolar inhibitor of IRAP with >120-fold selectivity over homologous enzymes. X-ray crystallographic analysis of IRAP in complex with this inhibitor suggest that interactions with the GAMEN loop is an unappreciated key determinant for potency and selectivity. Overall, our results suggest that alpha-hydroxy-beta-amino acid derivatives may constitute useful chemical tools and drug leads for this group of aminopeptidases. | |||
Discovery of Selective Nanomolar Inhibitors for Insulin-Regulated Aminopeptidase Based on alpha-Hydroxy-beta-amino Acid Derivatives of Bestatin.,Vourloumis D, Mavridis I, Athanasoulis A, Temponeras I, Koumantou D, Giastas P, Mpakali A, Magrioti V, Leib J, van Endert P, Stratikos E, Papakyriakou A J Med Chem. 2022 Jul 14. doi: 10.1021/acs.jmedchem.2c00904. PMID:35833347<ref>PMID:35833347</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 7z28" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Giastas P]] | [[Category: Giastas, P]] | ||
[[Category: Papakyriakou A]] | [[Category: Papakyriakou, A]] | ||
[[Category: Stratikos E]] | [[Category: Stratikos, E]] | ||
[[Category: Vourloumis D]] | [[Category: Vourloumis, D]] | ||
[[Category: Aminopeptidase]] | |||
[[Category: Bestatin]] | |||
[[Category: Bestatin analogue]] | |||
[[Category: Erap1]] | |||
[[Category: Hydrolase]] | |||
[[Category: Inhibitor]] | |||
[[Category: Metallopeptidase]] | |||
[[Category: Zinc]] | |||